Related Experiment Video

Updated: Apr 11, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.3K

Decrease of phosphorylated proto-oncogene CREB at Ser 133 site inhibits growth and metastatic activity of renal cell

Xue Wang1, Yu Ren, Haihui Zhuang

  • 1Ningbo University, School of Medicine , Ningbo 315211 , China.

Expert Opinion on Therapeutic Targets
|June 4, 2015
PubMed
Abstract

Insights

Phosphorylated CREB (pCREB) at Ser 133 drives renal cell carcinoma (RCC) growth and metastasis. Inhibiting pCREB significantly reduces tumor progression and spread, offering a potential therapeutic target for kidney cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Cyclic-AMP-responsive element-binding protein (CREB) is a proto-oncogenic transcription factor implicated in tumor progression.
  • Previous studies indicated that blocking the CREB binding site at Ser 133 inhibits target gene expression relevant to cancer.
  • The role of phosphorylated CREB (pCREB) at Ser 133 in renal cell carcinoma (RCC) warrants further investigation.

Purpose of the Study:

  • To investigate the role of phosphorylated CREB (pCREB) at Ser 133 in the growth and metastasis of renal cell carcinoma (RCC).
  • To determine if targeting pCREB at Ser 133 can inhibit RCC progression.

Main Methods:

  • Utilized immunohistochemistry, xenograft models in nude mice, and cell-based assays (proliferation, invasion, migration).
  • Employed fluorescent immunocytochemistry and Western analysis in an immortalized proximal tubule epithelial cell line and clear-cell RCC.
  • Bioinformatic analysis was performed to investigate potential molecular mechanisms.

Main Results:

  • Knockdown of pCREB significantly inhibited RCC cell growth in vivo.
  • Suppression of pCREB levels reduced cell migration and invasion in vitro, correlating with decreased expression of MMP-2, MMP-9, and EMT-related proteins.
  • Vimentin expression and localization remained unchanged, potentially due to the absence of a CRE sequence in its promoter.

Conclusions:

  • Decreasing the level of pCREB at Ser 133 effectively inhibits the growth and metastasis of renal cell carcinoma (RCC).
  • Targeting the Ser 133 site of pCREB presents a potential therapeutic strategy for managing RCC.
Keywords:
cyclic-AMP-responsive element-binding proteingrowthmetastasisrenal cell cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Induction and Analysis of Epithelial to Mesenchymal Transition10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K